Company’s Name: Johnson & Johnson’s

Johnson & Johnson is an American multinational corporation founded in 1886 that develops
medical devices, pharmaceutical and consumer packaged goods.

Operating areas:
J&J has more than 260 operating companies in 60 countries selling products around the world. It
has research facilities in more than a dozen countries and operates about 125 manufacturing
facilities in North America, Asia, Europe, and the Middle East.

Products:
1. Consumer health product:
Skin health products: Johnson & Johnson’s unique perspective as a leading healthcare company
together with technology expertise and in partnership with skin experts and dermatologists is to
create high performance prestige and mass products for healthy skin. It’s innovations include:
personalized skin health assessments, treatments for acne and eczema, gentle skin-loving
cleansers, moisturizers that repair the skin barrier and rebalance the skin’s microbiome, and
sunscreens that protect and defend against inflammation, premature aging, and skin cancer.
Self care products: This company meets the health needs of families across the globe through a
broad range of well-known and trusted healthcare and over-the-counter products. These include a
range of medicated and non-medicated solutions across key categories such as pain relief, allergy,
anti-diarrheal, antacids, nasal decongestants and cough and colds.
2. Medical devices:
In a radically changing environment, J&J's is making connections across science and technology
to combine their own expertise in surgery, orthopedics, vision and interventional solutions with
the big ideas of others to design and deliver physician and patient-centric products and solutions.
Orthopedics: This section includes products for Joint Reconstruction, Trauma, Spine, Sports
Medicine and Power Tools.

Surgery: In hospitals around the world, surgeons operate with confidence using trusted surgical
systems and instruments designed to provide the safest and most effective treatment for a range of
medical conditions. This sector includes, Ethicon, energy, Endomechanical, Bio-surgery, Wound
Closure, Ear- Nose-Throat.
3. Pharmaceuticals products:
It has products for Cardiovascular & Metabolic Disease, Pulmonary Hypertension, Infectious
Diseases & Vaccines, Neuroscience, Oncology.
Facilities:

Research and Development (R&D):

Globally there are several top pharmaceutical companies, however Johnson & Johnson stand out
about many of them with research and development being a top priority for the company.
Therefore, it is no surprise that J&J is among the top three pharmaceutical companies based on its
R&D spending. Johnson & Johnson also has one of the largest current R&D pipelines among
global pharmaceutical companies.

Company’s Name: Merck & Co. Inc.

An American multinational pharmaceutical company and one of the largest pharmaceutical

companies in the world. Merck is incorporated in New Jersey.

Operating areas: It operates as Merck & Co. in the United States and
Canada, the original Merck based in Darmstadt holds the rights to the Merck name everywhere
else. Merck & Co. is the world's seventh largest pharmaceutical company by market capitalization
and revenue. Its headquarters is located in Kenilworth, New Jersey.

Products:
1. Januvia:
A dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes. In 2013, Januvia was the
second largest selling diabetes drug worldwide, with $4.0 billion in worldwide sales. Januvia is
commonly paired with the generic anti-diabetes drug metformin. It has been popular due in part
because unlike many other diabetes drugs, it causes little or no weight gain and is not associated
with hypoglycemic episodes. Merck also sells a single pill combination drug containing both
Januvia and metformin under the trade name Janumet. There has been some concern that treatment
with Januvia and other DPP-IV inhibitors may be associated with a modestly increased risk of
pancreatitis.
2. Zeta:
It is a drug for hypercholesterolemia that acts by inhibiting the absorption of dietary cholesterol.
Sales in 2013 amounted to $2.7 billion. Zetia has been controversial, as it was initially approved
based on its impact on serum cholesterol levels without proof that it actually impacted the
incidence of cardiovascular disease. Results of the IMPROVE-IT study, however, introduced at
the 2014 Scientific Sessions of the American Heart Association, showed a statistically significant,
albeit modest, benefit in adding Zetia to simvastatin for high-risk, post-acute-coronary-syndrome
patients.
3. RRemicad:
Is a monoclonal antibody directed toward the cytokine TNF-Alpha and used for the treatment of a
wide range of autoimmune disorders. Remicade and other TNF-alpha inhibitors exhibit additive
therapeutic effects with methotrexate and improve quality of life. Adverse effects include
increased risk of infection and certain cancers. Merck had rights to the drug in certain areas, while
had rights in other areas in 2017, Merck announced a biosimilar to Remicade, Renflexis.
4. Gardasil:
It (recombinant human papilloma virus vaccine) is a vaccine against multiple serotypes of (HPV),
which is responsible for most cases of cervical cancer worldwide
5. Isentress:
It (raltegravir) is a human immunodeficiency virus integrase inhibitor for the treatment of HIV
infection. It is the first anti-HIV compound having this mechanism of action. Sales in 2013 were
$1.8 billion. It is part of one of several first line treatment regimens recommended by the United
States Department of Health and Human Services.
6. Keytruda:
Is an immune modulator for the treatment of cancer. On September 4, 2014, the US Food and Drug
Administration (FDA) approved as a breakthrough therapy for melanoma treatment. In clinical
trials, pembrolzumab provided partial tumor regression in about one quarter of patients, many of
whom have not seen further progression of their disease in over 6 months of follow-up.
7. Invanz:

Is an injectable antibiotic, rights to which Merck has owned since 1999. As of 2015, Merck was
in a legal dispute with the Taiwanese company Savior Lifetec over their attempt to secure rights
to sell in the United States.
Facilities:

Research and Development (R&D):

As of August 2014, Merck's research and development effort has led to the approval of more new
drugs than that of any other company. Research performed at Merck has led to U.S. FDA approval
of 63. In 2014, Merck's major products.

Company’s Name: AbbVie Inc.

AbbVie is a biopharmaceutical industry which was founded in 2013, 6

years ago.
Operating area: AbbVie's headquarter is in Lake bluff, illinois, United States.
It is operating it’s business in more than 170 countries.

Products:
Product list of this company includes the followings:
Pharmaceutical drugs:
1. Humira (adalimumab)
2. Imbruvica (ibrutinib)
3. Venclexta (venetoclax)
4. Zinbryta (daclizumab)
5. Kaletra (lopinavir)
6. Norvir (ritonavir)
7. Mavyret/Maviret (glecaprevir/pibrentasvir)
Facilities:

Research and Development (R&D):

AbbVie’s R&D is breaking new ground in complex disease areas like immunology, oncology,
neurology, virology and more. And our regulatory team safeguards the trust placed in AbbVie by
ensuring our products and practices adhere to the highest standards.

R&D Roles:

1. Data & statistical sciences (DSS)

2. Discovery
3. Global medical affairs
4. Pharmaceutical development
5. Pharmacovigilance
6. Pharmacology
7. Quality assurance
8. Chemistry, manufacturing & controls (CMC)
9. Global labeling, advertising & promotion
10. Global product strategy
11. Regulatory operations, policy & intelligence
 Company’s Name: Gilead Science Inc.

Gilead Sciences, an American biotechnology company that researches, develops and

commercializes drugs. The company focuses primarily on antiviral drugs used in the treatment of
HIV, hepatitis B, hepatitis C, and influenza, including Harvoni and Sovaldi. It was founded in
1987, 32 years ago. Is headquarter is in Foster city, California, United States.

Operating areas:
Gilead sciences operates their business worldwide. Their headquarter is in Foster city, California,
United States.

Products:
Gilead seeks to develop products that represent advancements by offering enhanced modes of
delivery, more convenient treatment regimens, improved resistance profiles, reduced side effects
and greater efficacy. Through their own research and partnerships with universities, medical
research institutions and global pharmaceutical leaders, Gilead is rapidly and efficiently making
scientific and clinical advancements that raise the standard for new therapeutics that treat life-
threatening diseases.

Gilead Sciences has products for the following diseases or segments:

1. HIV/AIDS
2. Liver Disease
3. Hematology / Oncology
4. Cardiovascular
5. Inflammation / Respiratory
6. Other Medicines

Facilities:
Research and Development (R&D):
Since the founding of Gilead in 1987, Gilead has focused on developing and delivering
medications that advance the treatment of life-threatening diseases. The commercial success of it’s
products provides us with the resources to generate new clinical data defining their profiles and
supports our development of new therapeutic advancements. As it brings new products into clinical
development, it’s goal remains the same–to discover, develop and commercialize therapeutics that
advance patient care.
Gilead’s research and development programs currently focus on potential treatments in
HIV/AIDS, liver diseases, hematology and oncology, inflammatory and respiratory diseases, and
cardiovascular conditions. Apart from that, In July 14, 2019, Gilead and Galapagos enter into
transformative research and development collaboration. As per terms of the deal, Galapagos will
secure $3.95bn upfront payment and $1.1bn equity investment from Gilead. It intends to use the
proceeds to expend and enhance it’s research and development programs.